New Approaches to Shifting the Migraine Treatment Paradigm
Frontiers in Pain Research, 2022 The standard of care paradigm for migraine treatment has been based almost exclusively on approaches that grew out of the happenstance use of market pharmaceuticals.
Brian Johnson, Frederick G. Freitag
doaj +1 more source
Triptans and CGRP blockade - impact on the cranial vasculature [PDF]
, 2017 The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide ...
Alejandro Labastida-Ramírez +9 more
core +3 more sources
Up to date on the use of triptans for child and adolescent migraine: “the state of the art” [PDF]
, 2001 The introduction of triptans, in the early 1990s, has improved the therapy for acute migraine attack, offering a new quality of life for those patients who suffer from this disabling neurological disorder. Epidemiological data point out that about 10% of
D. CALDERONI +2 more
core +1 more source
NSAIDs and Triptans – a (not) New Treatment Option for Migraine
Neurologijos seminarai, 2023 Every day, around 7% of population will experience headache caused by migraine. Migraine is one of the leading causes of years lived with disability, and it also causes significant negative economic impact, as most as the affected population is of ...
B. Kakta, Rasa Mameniškienė
doaj +3 more sources
Journal of Primary Care & Community Health, 2020 Introduction: Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors.
David W. Dodick +11 more
doaj +1 more source
Eletriptan in the management of acute migraine. An update on the evidence for efficacy, safety, and consistent response [PDF]
, 2016 Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks.
Capi, Matilde +6 more
core +1 more source
Acute treatment of migraine: quo vadis? [PDF]
, 2017 Migraine represents the third cause of disability in the worldwide population aged under 50 years. Facing this enormous social impact, only onabotulinumtoxinA has been evaluated, on serendipity basis, as effective chronic migraine preventative ...
Martelletti, Paolo
core +1 more source
The therapeutic armamentarium in migraine is quite elderly. [PDF]
, 2014 Global Burden of Disease 2010 study considers migraine as one of the most important noncommunicable diseases in the world, classifying it third in terms of global prevalence (14.70%): it sums up the 54.19% of all the years of life lived with disabilities
Martelletti, Paolo
core +1 more source
Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification. [PDF]
, 2009 There is evidence that the prevalence of migraine in children and adolescents may be increasing. Current theories of migraine pathophysiology in adults suggest activation of central cortical and brainstem pathways in conjunction with the peripheral ...
A Ferrari +52 more
core +1 more source
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. [PDF]
, 2017 BackgroundDFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-β-D-Maltopyranoside (DDM).
Allenby, Kent +5 more
core +1 more source